Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2513902 | 1.00 | CTSB (0.58) | CTSBCYP2C9ALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL2513906 | 1.00 | CTSB (0.58) | CTSBCYP2C9ALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL15999199 | 0.94 | ACHE (0.56) | CTSBCYP2C9ALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL1421723 | 0.89 | CTSB (0.60) | CTSBCYP2C9ALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL2509364 | 0.88 | MAOB (0.63) | CTSBCYP2C9ALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL2509369 | 0.88 | MAOB (0.63) | CTSBCYP2C9ALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL13339132 | 0.88 | MAOB (0.63) | CTSBCYP2C9ALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL13339109 | 0.85 | ACHE (0.68) | MAOBMAPTKDM4ELMNAACHE | |
| SCHEMBL2486368 | 0.85 | ACHE (0.68) | MAOBMAPTKDM4ELMNAACHE | |
| SCHEMBL2486370 | 0.85 | ACHE (0.68) | MAOBMAPTKDM4ELMNAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140248634-A1 | VIMENTIN AS A BIOMARKER FOR THE PROGRESSION OF MYELOPROLIFERATIVE NEOPLASMS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140248634-A1 | VIMENTIN AS A BIOMARKER FOR THE PROGRESSION OF MYELOPROLIFERATIVE NEOPLASMS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2014-09-04 | — | — | US | disclosed |
| WO-2013019655-A2 | VIMENTIN AS A BIOMARKER FOR THE PROGRESSION OF MYELOPROLIFERATIVE NEOPLASMS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2013-02-07 | — | — | WO | disclosed |
| US-20110301159-A1 | KINASE INHIBITOR COMPOUNDS | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301159-A1 | KINASE INHIBITOR COMPOUNDS | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2010068710-A2 | KINASE INHIBITOR COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301159-A1 | KINASE INHIBITOR COMPOUNDS | JAK2, JAK1, JAK3 | CTSB 1994/4885CYP2C9 4646/4885ALOX15 2374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.